- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
New strategy for treating cancer recognised with Victoria Prize
14 December 2021
Anne Voss have won the 2021 Victoria Prize.
WEHI Associate Professor Tim Thomas and Professor Anne Voss have been awarded the 2021 Victoria Prize for Science and Innovation in Life Sciences, for their novel research that has led to a new chemical strategy to treat cancer.
The $50,000 prize recognises the ground-breaking research conducted by the scientists in finding a novel anti-cancer strategy that doesn’t trigger the harmful side-effects caused by conventional cancer treatments.
The researchers, who have worked together for more than 30 years, made discoveries that uncovered key functions of the MYST family of proteins and validated them as novel targets for anti-cancer therapies. They also led a collaborative team that discovered a new type of anti-cancer compound that puts cancer cells into a ‘permanent sleep’.
At a glance
- Professor Anne Voss and Associate Professor Tim Thomas have been awarded the 2021 Victoria Prize for Science and Innovation in Life Sciences.
- The team undertook novel research that led to a new chemical strategy for treating cancer by putting cancer cells to ‘sleep’.
- Compounds based on the early-stage research of Professor Voss and Associate Professor Thomas progressed into clinical trials in late 2020.
International expertise
Professors Voss and Associate Professor Thomas are international experts in the biology of MYST family proteins.
Working with the Cancer Therapeutics (CTx) CRC, researchers from the Monash Institute of Pharmaceutical Sciences (MIPS), CSIRO and St Vincent’s Institute of Medical Research, the researchers investigated ways to inhibit MYST proteins to treat cancer. A large chemical compound screen led to the development of novel inhibitors of the MYST proteins. This was followed by a collaboration with researchers from the Peter MacCallum Cancer Centre to expand the potential cancer spectrum that may benefit from MYST inhibitor treatment.
Compounds based on the early-stage discoveries of Professor Voss and Associate Professor Thomas progressed into clinical trials in late 2020.
Putting cancer cells to sleep
Professor Voss said the duo’s research, conducted with their team at WEHI, identified the first class of anti-cancer compounds that cause some cancer cells to permanently exit the cell cycle – putting cancer cells to ‘sleep’.
“Rather than causing potentially dangerous DNA damage, this new class of anti-cancer compounds puts cancer cells into a state of cell cycle arrest termed ‘cellular senescence’,” she said.
“Crucially, in arresting tumour growth they do not damage the cells’ DNA. This is a critical difference between this new class of compounds and standard cancer therapies, such as chemotherapy and radiotherapy, which work by causing irreversible DNA damage, causing collateral damage to healthy cells.”
Associate Professor Thomas said the duo had spent more than 20 years studying the family of proteins.
“Our initial research led to discovery of the MYST family protein KAT6B, and later to determine the biological functions of the other MYST proteins and their role in cellular senescence and cancer. Armed with this knowledge, we began to look for ways of inhibiting the protein to treat cancer,” he said.
“This new class of anti-cancer compounds was effective in preventing cancer progression in our preclinical cancer models. We are extremely excited about the potential that they hold as an entirely new tool for fighting cancer.”
Following publication of the work in Nature in 2018, the research attracted worldwide media attention. They have also been recognised by joint an individual awards, including the 2021 Australian Academy of Technology and Engineering (ATSE) Clunies Ross Knowledge Commercialisation Award jointly with Professor Jonathan Baell (MIPS).
Professor Voss said she and Associate Professor Thomas were honoured to receive this award.
“We are grateful to veski for this award, and thank the team of 50 researchers who worked on this project with us. We hope our work highlights the importance of long-term investment in translational research to improve the lives of the millions of people worldwide impacted by cancer.”
Significant achievement
Institute director Professor Doug Hilton said the scientists’ were pioneers in their field who have made significant discoveries in advancing cancer treatment.
“The new class of drugs could provide an important alternative for people with cancer and has already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying relapse,” Professor Hilton said.
“The research is particularly significant considering that this family of genes had previously been considered ‘undruggable’ by the scientific community. Their collaborative approach to research and long-term commitment to improving the lives of people in Australia and around the world is admirable and I congratulate Anne and Tim on this well-deserved award.”
The Victoria Prize was first awarded in 1998 and celebrates leadership, determination, endeavour and creativity, while highlighting the many ways in which Victoria leads the way in terms of research and development of international significance.
Media inquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
In a world first, Institute scientists and collaborators have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies.
WEHI scientists have revealed that a gene called PHF6 plays a powerful role in protecting against blood cancer. The study showed how a breakdown in the gene’s function could accelerate the development of T cell acute lymphoblastic leukaemia (T-ALL).
Want to be informed of our most exciting discoveries? Subscribe to our quarterly newsletter, Illuminate.